7 results
Systemic Lupus Erythematosus (SLE) - Diagnosis and Management Summary
 • Epidemiology: 10-180/100,000, Typically Age 20-40, F:M
Diagnosis and Management ... - Anti-dsDNA - Positive ... Anti-histone - Positive ... life-threatening • Treatment ... #Summary #rheumatology
Drug Induced Lupus vs SLE
Drug Induced Lupus (DIL):
 • Epidemiology: -10% of all lupus cases, drug-dependent,
life-threatening • Treatment ... Usual therapeutic management ... Lupusreference #druginduced ... #table #rheumatology ... #diagnosis #management
Hemophagocytic Lymphohistiocytosis (HLH)
Pathophysiology: Triggering factor (infection,...)→Activation of CD8 T cells (IFN-y) → Excessive activation of macrophages
→Activation of CD8 ... Autoimmune diseases: SLE ... Lymphohistiocytosis #diagnosis #management ... #treatment #summary ... #rheumatology
Behçet's Syndrome
Systemic disease associated with inflammation of multiple organs, small-vessel vasculitis and large-vessel vasculopathy
Epidemiology:
 • Young
Skin lesions • Positive ... Oral aphthae : SLE ... Arthritis, AS Treatment ... Syndrome #diagnosis #management ... signs #symptoms #rheumatology
Drug Induced Lupus (DIL)
 • Epidemiology: -10% of all lupus cases, drug-dependent, 4:1 to 1:1 F:M
is rare in DIL, SCLE-DIL ... Anti-histone - Positive ... Lupusreference #DrugInduced ... #Lupus #DIL #rheumatology ... #management
Sjogren's Syndrome Overview

Epidemiology:
• F > M: 9:1
• 5-6th Decades (can be any age)

Autoimmune exocrinopathy multisystemic disease
overlaps with RA, SLE ... Nephrogenic DI Hematologic ... Adenocarcinoma Treatment ... Sjogrens #Syndrome #Rheumatology ... #Diagnosis #Management
Anti-NXP-2 Dermatomyositis

What?
DM with generalized subcutaneous edema
Pts have more myalgias, more severe weakness, and an increased prevalence
NXP-2 antibody positive ... of anti-NXP-2-positive ... patients Treatment ... Dermatomyositis #diagnosis #management ... #rheumatology #